Articles

admin

4D Molecular Therapeutics Announces Updates on Clinical Pipeline and Additional Preclinical Programs

January 9, 2023 Download PDF EMERYVILLE, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) — 4D Molecular Therapeutics, Inc. (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic medicines, announced product pipeline portfolio updates and preclinical product candidate additions for its large market ophthalmology and pulmonology programs, as well as clinical…

View details
Mirum Pharmaceuticals Announces Preliminary Unaudited LIVMARLI 2022 Net Revenue and Provides Corporate Updates

– $76 million in total revenue and $74 million net product sales anticipated for LIVMARLI for 2022, preliminary and unaudited – sNDA for LIVMARLI in PFIC submission planned for first quarter 2023 – Multiple data analyses planned in 2023 advancing late-stage cholestasis programs FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today provided a preview…

View details
Mirum Pharmaceuticals to Present at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023

FOSTER CITY, Calif.–(BUSINESS WIRE)– Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the identification, acquisition, development and commercialization of novel therapies for debilitating rare and orphan diseases, today announced that it will present at the annual J.P. Morgan Healthcare Conference taking place January 9-12, 2023. Presentation and Q&A Session Visit the Investors and Media section of…

View details
System analytics

What we do Maecenas et felis consequat Nullam mollis – massa id volutpat. Suspendisse neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris Suspendisse ipsum – amet neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris. Integer eu aliquet dolor. Suspendisse…

View details
Human resources

What we do Maecenas et felis consequat Nullam mollis – massa id volutpat. Suspendisse neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris Suspendisse ipsum – amet neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris. Integer eu aliquet dolor. Suspendisse…

View details
Brand & strategy

What we do Maecenas et felis consequat Nullam mollis – massa id volutpat. Suspendisse neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris Suspendisse ipsum – amet neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris. Integer eu aliquet dolor. Suspendisse…

View details
Marketing planning

What we do Maecenas et felis consequat Nullam mollis – massa id volutpat. Suspendisse neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris Suspendisse ipsum – amet neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris. Integer eu aliquet dolor. Suspendisse…

View details
Business optimisation

What we do Maecenas et felis consequat Nullam mollis – massa id volutpat. Suspendisse neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris Suspendisse ipsum – amet neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris. Integer eu aliquet dolor. Suspendisse…

View details
Business development

What we do Maecenas et felis consequat Nullam mollis – massa id volutpat. Suspendisse neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris Suspendisse ipsum – amet neque elit, consequat nec tempus sit amet, luctus id erat volutpat magna. Integer nec viverra mauris. Integer eu aliquet dolor. Suspendisse…

View details